Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Publication date: February 2017
Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 1
Author(s): Kathryn C. Arbour, Gregory J. Riely

Teaser

Anaplastic lymphoma kinase (ALK) gene rearrangements occur in a small portion of patients with non–small cell lung cancer (NSCLC). These gene rearrangements lead to constitutive activation of the ALK kinase and subsequent ALK-driven tumor formation. Patients with tumors harboring such rearrangements are highly sensitive to ALK inhibitors, such as crizotinib, ceritinib, and alectinib. Resistance to these kinase inhibitors occurs through several mechanisms, resulting in ongoing clinical challenges. This review summarizes the biology of ALK-positive lung cancer, methods for diagnosing ALK-positive NSCLC, current FDA-approved ALK inhibitors, mechanisms of resistance to ALK inhibition, and potential strategies to combat resistance.


http://ift.tt/2fDvFIb